Literature DB >> 20696661

Use of folic acid-containing supplements after a diagnosis of colorectal cancer in the Colon Cancer Family Registry.

Rebecca S Holmes1, Yingye Zheng, John A Baron, Lin Li, Gail McKeown-Eyssen, Polly A Newcomb, Mariana C Stern, Robert W Haile, William M Grady, John D Potter, Loic Le Marchand, Peter T Campbell, Jane C Figueiredo, Paul J Limburg, Mark A Jenkins, John L Hopper, Cornelia M Ulrich.   

Abstract

BACKGROUND: Supplement use among cancer patients is high, and folic acid intake in particular may adversely affect the progression of colorectal cancer. Few studies have evaluated the use of folic acid-containing supplements (FAS) and its predictors in colorectal cancer patients.
OBJECTIVE: To assess the use of FAS, change in use, and its predictors after colorectal cancer diagnosis.
DESIGN: We used logistic regression models to investigate predictors of FAS use and its initiation after colorectal cancer diagnosis in 1,092 patients recruited through the Colon Cancer Family Registry.
RESULTS: The prevalence of FAS use was 35.4% before and 55.1% after colorectal cancer diagnosis (P = 0.004). Women were more likely than men to use FAS after diagnosis [odds ratio (OR), 1.47; 95% confidence interval (95% CI), 1.14-1.89], as were those consuming more fruit (P(trend) < 0.0001) or vegetables (P(trend) = 0.001), and U.S. residents (P < 0.0001). Less likely to use FAS after diagnosis were nonwhite patients (OR, 0.66; 95% CI, 0.45-0.97), current smokers (OR, 0.67; 95% CI, 0.46-0.96), and those with higher meat intake (P(trend) = 0.03). Predictors of FAS initiation after diagnosis were generally similar to those of FAS use after diagnosis, although associations with race and vegetable intake were weaker and those with exercise stronger.
CONCLUSIONS: Our analysis showed substantial increases in the use of FAS after diagnosis with colorectal cancer, with use or initiation more likely among women, Caucasians, U.S. residents, and those with a health-promoting life-style. IMPACT: Studies of cancer prognosis that rely on prediagnostic exposure information may result in substantial misclassification. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20696661      PMCID: PMC3523172          DOI: 10.1158/1055-9965.EPI-09-1097

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  44 in total

Review 1.  Multivitamin-multimineral supplements: who uses them?

Authors:  Cheryl L Rock
Journal:  Am J Clin Nutr       Date:  2007-01       Impact factor: 7.045

2.  Folate and cancer--timing is everything.

Authors:  Cornelia M Ulrich; John D Potter
Journal:  JAMA       Date:  2007-06-06       Impact factor: 56.272

3.  Nutrient intake from multivitamin/mineral supplements is similar among users from five ethnic groups: the Multiethnic Cohort Study.

Authors:  Song-Yi Park; Suzanne P Murphy; Carrie L Martin; Laurence N Kolonel
Journal:  J Am Diet Assoc       Date:  2008-03

Review 4.  Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review.

Authors:  Christine M Velicer; Cornelia M Ulrich
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

5.  Lifestyle and diet in people using dietary supplements: a German cohort study.

Authors:  Annika Reinert; Sabine Rohrmann; Nikolaus Becker; Jakob Linseisen
Journal:  Eur J Nutr       Date:  2007-03-21       Impact factor: 5.614

6.  Folate and colorectal cancer: an evidence-based critical review.

Authors:  Young-In Kim
Journal:  Mol Nutr Food Res       Date:  2007-03       Impact factor: 5.914

Review 7.  Folate status: effects on pathways of colorectal carcinogenesis.

Authors:  Sang-Woon Choi; Joel B Mason
Journal:  J Nutr       Date:  2002-08       Impact factor: 4.798

8.  Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer.

Authors:  Polly A Newcomb; John Baron; Michelle Cotterchio; Steve Gallinger; John Grove; Robert Haile; David Hall; John L Hopper; Jeremy Jass; Loïc Le Marchand; Paul Limburg; Noralane Lindor; John D Potter; Allyson S Templeton; Steve Thibodeau; Daniela Seminara
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-11-02       Impact factor: 4.254

9.  Aspirin and folic acid for the prevention of recurrent colorectal adenomas.

Authors:  Richard F A Logan; Matthew J Grainge; Vic C Shepherd; Nicholas C Armitage; Kenneth R Muir
Journal:  Gastroenterology       Date:  2007-10-10       Impact factor: 22.682

10.  Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.

Authors:  Bernard F Cole; John A Baron; Robert S Sandler; Robert W Haile; Dennis J Ahnen; Robert S Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard I Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Douglas J Robertson; Gerald J Beck; John H Bond; Tim Byers; Jack S Mandel; Leila A Mott; Loretta H Pearson; Elizabeth L Barry; Judy R Rees; Norman Marcon; Fred Saibil; Per Magne Ueland; E Robert Greenberg
Journal:  JAMA       Date:  2007-06-06       Impact factor: 56.272

View more
  10 in total

1.  Post-cancer diagnosis dietary inflammatory potential is associated with survival among women diagnosed with colorectal cancer in the Women's Health Initiative.

Authors:  Jiali Zheng; Fred K Tabung; Jiajia Zhang; E Angela Murphy; Nitin Shivappa; Judith K Ockene; Bette Caan; Candyce H Kroenke; James R Hébert; Susan E Steck
Journal:  Eur J Nutr       Date:  2019-04-06       Impact factor: 5.614

Review 2.  Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.

Authors:  Mukesh Verma; Muin J Khoury; John P A Ioannidis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-14       Impact factor: 4.254

3.  Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome.

Authors:  Rowena Chau; Seyedeh Ghazaleh Dashti; Driss Ait Ouakrim; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Ingrid M Winship; Joanne P Young; Graham G Giles; Finlay A Macrae; Alex Boussioutas; Susan Parry; Jane C Figueiredo; A Joan Levine; Dennis J Ahnen; Graham Casey; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Stephen N Thibodeau; Noralane M Lindor; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win
Journal:  Int J Epidemiol       Date:  2016-04-10       Impact factor: 7.196

Review 4.  Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research.

Authors:  Joanne W Elena; Lois B Travis; Naoko I Simonds; Christine B Ambrosone; Rachel Ballard-Barbash; Smita Bhatia; James R Cerhan; Patricia Hartge; Rebecca S Heist; Lawrence H Kushi; Timothy L Lash; Lindsay M Morton; Kenan Onel; John P Pierce; Leslie L Robison; Julia H Rowland; Deborah Schrag; Thomas A Sellers; Daniela Seminara; Xiao Ou Shu; Nancy E Thomas; Cornelia M Ulrich; Andrew N Freedman
Journal:  J Natl Cancer Inst       Date:  2012-11-28       Impact factor: 13.506

5.  MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland.

Authors:  Amit A Negandhi; Angela Hyde; Elizabeth Dicks; William Pollett; Banfield H Younghusband; Patrick Parfrey; Roger C Green; Sevtap Savas
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

6.  Low-dose methotrexate enhances cycling of highly anaplastic cancer cells.

Authors:  Maria Grazia Cipolleschi; Ilaria Marzi; Elisabetta Rovida; Massimo Olivotto; Persio Dello Sbarba
Journal:  Cell Cycle       Date:  2016-11-14       Impact factor: 4.534

Review 7.  Cancer survivorship: an integral part of Europe's research agenda.

Authors:  Pernilla Lagergren; Anna Schandl; Neil K Aaronson; Hans-Olov Adami; Francesco de Lorenzo; Louis Denis; Sara Faithfull; Lifang Liu; Franḉoise Meunier; Cornelia Ulrich
Journal:  Mol Oncol       Date:  2019-01-08       Impact factor: 6.603

Review 8.  Methylenetetrahydrofolate reductase polymorphisms and colorectal cancer prognosis: A meta-analysis.

Authors:  Xin-Lin Chen; Yu-Mei Wang; Fei Zhao; Zheng Chen; Xiaofei Yang; Cong Sun; Yunpeng Gao; Tian-Ge Yang; Guo Tian; Yi-Ming Chen; Shui-Lian Zhu; Xiao-Bing Lin; Feng-Bin Liu
Journal:  J Gene Med       Date:  2019-08-06       Impact factor: 4.565

9.  Surface modification of gold nanoparticles with 6-mercapto-1-hexanol to facilitate dual conjugation of protoporphyrin IX and folic acid for improving the targeted photochemical internalization.

Authors:  Armin Imanparast; Neda Attaran; Hossein Eshghi; Ameneh Sazgarnia
Journal:  Iran J Basic Med Sci       Date:  2022-08       Impact factor: 2.532

10.  Folic acid supplementation promotes mammary tumor progression in a rat model.

Authors:  Shaidah Deghan Manshadi; Lisa Ishiguro; Kyoung-Jin Sohn; Alan Medline; Richard Renlund; Ruth Croxford; Young-In Kim
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.